On September 23, Geelong reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., received the "Acceptance Letter" issued by the National Medical Products Administration on September 23, 2024. The pharmaceutical product is named HSK46575 tablets and is intended for the treatment of prostate cancer.
海思科(002653.SZ)：子公司HSK46575片IND申请获受理
Haisco Pharmaceutical Group (002653.SZ): Subsidiary HSK46575's IND application accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.